Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Hyperbaric oxygen therapy may be an efficacious therapy for IBD

A study published in the Alimentary Pharmacology & Therapeutics quantifies the safety and efficacy of hyperbaric oxygen therapy for Crohn's disease and ulcerative colitis.

News image

Hyperbaric oxygen therapy (HBOT) provides 100% oxygen under pressure, which increases tissue oxygen levels, relieves hypoxia and alters inflammatory pathways.

Although there is experience using HBOT in Crohn's disease and ulcerative colitis, the safety and overall efficacy of hyperbaric oxygen therapy in inflammatory bowel disease (IBD) is unknown.

Dr Corey Siegel and colleagues from the United Kingdom quantified the safety and efficacy of hyperbaric oxygen therapy for Crohn's disease and ulcerative colitis.

The rate of adverse events with hyperbaric oxygen therapy for IBD was compared to the expected rate of adverse events with hyperbaric oxygen therapy.

MEDLINE, EMBASE, Cochrane Collaboration and Web of Knowledge were systematically searched using the PRISMA standards for systematic reviews.

The research team identified 17 studies involving 613 patients.
In ulcerative colitis, the overall response rate to hyperbaric oxygen therapy was 100%
Alimentary Pharmacology & Therapeutics

The team noted that the overall response rate was 86%.

The overall response rate for perineal Crohn's disease was 88%.

Of the 40 ulcerative colitis patients with endoscopic follow-up reported, the overall response rate to hyperbaric oxygen therapy was 100%.

During the 8924 treatments, the team found a total of 9 adverse events, 6 of which were serious.

The team observed that the rate of adverse events with hyperbaric oxygen therapy in IBD is lower than that seen when utilizing HBOT for other indications.

The risk of bias across studies was high.

Dr Siegel and team conclude, "Hyperbaric oxygen therapy is a relatively safe and potentially efficacious treatment option for IBD patients."

"To understand the true benefit of hyperbaric oxygen therapy in IBD, well-controlled, blinded, randomized trials are needed for both Crohn's disease and ulcerative colitis."

Aliment Pharmacol Ther 2014: 39(11): 1266–1275
14 May 2014

Go to top of page Email this page Email this page to a colleague

 20 August 2014

Advanced search
 20 August 2014 
Chemotherapy-induced gastrointestinal mucositis
 20 August 2014 
Rectal surgery mortality
 20 August 2014 
Stool methylated DNA markers and colorectal cancer resection
 19 August 2014 
Variability of colonoscopy preparation instructions
 19 August 2014 
Recurrent C. difficile infection in out-patients
 19 August 2014 
Racial disparities and colon cancer
 18 August 2014 
Metabolomic analysis in IBD
 18 August 2014 
Enhanced T-cell response in acute-on-chronic Hep B
 18 August 2014 
The evolution of urban C. difficile
 15 August 2014 
Population-based fecal immunochemical test screening
 15 August 2014 
Abdominal pain in IBS
 15 August 2014 
Gene expression biomarker in ulcerative colitis
 14 August 2014 
Transnasal vs transoral endoscopy
 14 August 2014 
Radiation exposure in gastroenterology
 14 August 2014 
Dietary fibre and diverticular disease
 13 August 2014 
Adherence to Rome criteria in functional dyspepsia
 13 August 2014 
Fecal immunochemical test screening
 13 August 2014 
Flexible sigmoidoscopy screening
 12 August 2014 
Eosinophilic esophagitis and celiac disease
 12 August 2014 
Management of Lynch syndrome
 12 August 2014 
Risk of cancer under immunosuppressive therapy in IBD
 11 August 2014 
Risk of GI bleeds with anticoagulants
 11 August 2014 
Social media in health-care
 11 August 2014 
Gut microbiota in chemotherapy-induced GI mucositis
 08 August 2014 
Surgeon volume and esophagectomy survival
 08 August 2014 
Endoscopy nurse-administered propofol sedation performance
 08 August 2014 
Therapy for biliary tract cancer
 07 August 2014 
Smoking cessation and age of onset of ulcerative colitis
 07 August 2014 
Global consensus on perianal fistulizing Crohn's disease
 07 August 2014 
Colonoscopy length and training duration
 06 August 2014 
Hepatitis C virus infection in the United States
 06 August 2014 
Pediatric to adult IBD care
 06 August 2014 
Biomarker of disease activity in IBD
 05 August 2014 
Rising incidence of celiac disease
 05 August 2014 
Socioeconomic status and IBS
 05 August 2014 
Bowel dysfunction after sphincter-preserving rectal cancer surgery
 04 August 2014 
Relative adrenal insufficiency and chronic liver disease
 04 August 2014 
Colonoscopy screening protocol for liver transplant recipients
 04 August 2014 
Patient-reported outcomes after upper GI bleed
 01 August 2014 
Capsule colonoscopy vs CT colonography for polyp screening
 01 August 2014 
Complications after obesity surgery
 01 August 2014 
Fully covered self-expanding metal stents for benign biliary strictures
 31 July 2014 
Diverticular disease and colon cancer
 31 July 2014 
Biomarkers in liver fibrosis
 31 July 2014 
Risk factors of large colorectal polyps
 30 July 2014 
Interval between screening colonoscopies
 30 July 2014 
Small intestinal permeability in diarrhea predominant IBS
 30 July 2014 
Mineral rich water and constipation
 29 July 2014 
Fluticasone in eosinophilic esophagitis
 29 July 2014 
Causes of GI bleeding in cirrhosis
 29 July 2014 
ALT increases in Hep B
 28 July 2014 
Statins reduce Barrett's
 28 July 2014 
Score predicts risk for Barrett’s esophagus
 28 July 2014 
Gastric cancer prevention
 25 July 2014 
De-escalation of therapy in IBD
 25 July 2014 
Bionic pancreas in type 1 diabetes
 25 July 2014 
Primary care physician counselling and colonoscopy
 24 July 2014 
Diagnostic tool for obscure-overt GI bleeding
 24 July 2014 
Statin use and Barrett’s esophagus
 24 July 2014 
Atopy and functional GI disorders

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us